ArticlePrecision radiation oncology2024
Exploration of individualized neoadjuvant therapy model for operable esophageal cancer: A Surveillance, Epidemiology, and End Results database analysis.
Article in Precision radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of preoperative controlling nutritional status score with clinical outcomes among surgical patients with esophageal cancer: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Radiation dose and pathological complete response rate of neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma: a model-based dose-response meta-analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- A novel prognostic model integrating the skeletal muscle index and systemic immune-inflammation index improves outcome prediction in unresectable esophageal squamous cell carcinoma.The British journal of radiology · 2026Article
- Activation of NF-κB signaling pathway in GSDME-low esophageal squamous cell carcinoma cells enhances radioresistance.Journal of translational medicine · 2026Article
- Automated segmentation of esophageal squamous cell carcinoma in contrast-enhanced free-breathing 3D-GRE: a comparative study of UNet, nnUNet, and UMamba for tumor delineation.BMC medical imaging · 2025Article
- Preoperative esophageal cancer staging assessment based on intravoxel incoherent motion and apparent diffusion coefficient: a comparative study of maximum-diameter slice region of interest and whole volume of interest analysis.BMC medical imaging · 2025Article
- Construction and validation of a necroptosis-related lncRNA signature for predicting the prognosis of gastrointestinal cancer patients.Frontiers in immunology · 2025Article
- Prognostic impact of CT-derived muscle-adipose index change in patients with inoperable esophageal squamous cell carcinoma undergoing chemoradiotherapy.Frontiers in oncology · 2025Article
- Integration of Delta-Radiomics Features and Inflammatory Biomarkers for Neoadjuvant Chemo-Immunotherapy Efficacy in Locally Advanced Esophageal Squamous Cell Carcinoma.Journal of inflammation research · 2025Article
- Clinicopathologic features of superficial esophageal squamous cell carcinoma in different infiltrative growth pattern.Frontiers in oncology · 2025Article
- Exploration of individualized neoadjuvant therapy model for operable esophageal cancer: A Surveillance, Epidemiology, and End Results database analysis.Precision radiation oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to examine the individualized neoadjuvant therapies for operable esophageal cancer. Methods and Materials: Data of 95,444 patients diagnosed with esophageal cancer between 2010 and 2017 were collected from the Surveillance, Epidemiology, and End Results database. The effectiveness of neoadjuvant chemoradiotherapy (nCRT), neoadjuvant chemotherapy (nCT), and surgery alone was compared in patients with stage II esophageal cancer. Patients with stage III disease were divided into "local invasive type" group (type I, T3N1M0, T4N0-1M0) and "regional metastatic type" group (type II, T1-2N2-3M0) according to the tumor invasion pattern. The effectiveness of nCRT and nCT in different patterns was compared. Results: In 2,706 patients with stage II disease, a statistical difference was observed in the overall survival (OS) between nCRT (85.1%), nCT (3.0%), and surgery alone (11.9%, Conclusions: nCRT is recommended for stage II esophageal cancer. In patients with stage III, those with "local invasive type" may greatly benefit from nCRT, while those with "regional metastatic type" may greatly benefit from nCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.